<DOC>
	<DOCNO>NCT03037489</DOCNO>
	<brief_summary>This multicentre , open-label , one-arm Phase II extension study evaluate safety tolerability MIV-711 patient knee joint osteoarthritis ( OA ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability MIV-711 Osteoarthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Previously enrol MIV711201 study include completion Visit 8 either Receiving MIV711 200 mg nonsignificant clinical worsen primary endpoint define NRS increase ≤2 OR Receiving placebo clinically significant worsen primary endpoint define NRS increase ≥2 The presence inflammatory arthritis Any generalize pain condition may interfere evaluation target knee pain ( e.g. , fibromyalgia ) judge investigator . Any clinically severe significant uncontrolled concurrent illness , , opinion Investigator , would impair ability give inform consent take part complete clinical study . Known suspect intolerance hypersensitivity investigational product , closely related compound , state ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>